Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MCLA-129
i
Other names:
MCLA-129, MCLA129, MCLA 129
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3)
News
Trials
Company:
Betta Pharma, Merus
Drug class:
EGFR inhibitor, c-MET inhibitor
Related drugs:
‹
cetuximab (347)
osimertinib (301)
erlotinib (235)
afatinib (227)
gefitinib (194)
panitumumab (123)
lapatinib (107)
neratinib (102)
pyrotinib (79)
brigatinib (50)
icotinib (45)
aumolertinib (39)
amivantamab-vmjw (25)
firmonertinib (14)
mobocertinib (12)
lazertinib (12)
BGB-283 (12)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
nimotuzumab (6)
BLU-945 (6)
ASLAN001 (6)
BBT-176 (5)
CL-387785 (5)
GB263T (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
tomuzotuximab (4)
JIN-A02 (4)
TAS2940 (4)
VRN11 (4)
MET306 (4)
EGF816 (4)
AFM24 (3)
BLU-701 (3)
GC-1118A (3)
necitumumab (3)
befotertinib (3)
zorifertinib (3)
BCA101 (3)
S95026 (3)
ASP8273 (3)
DZD9008 (3)
SZMD4 (3)
ACE2016 (2)
BI-732 (2)
BLU-451 (2)
Bay846 (2)
ERAS-801 (2)
OBX02-011 (2)
olmutinib (2)
QL1203 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
APL-103 (1)
BAY 2927088 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
KKI04 (1)
PH001 (1)
rilertinib (1)
TAS3351 (1)
TRX-221 (1)
WSD0922 (1)
JMT101 (1)
S-222611 (1)
HMPL-813 (1)
SI-B001 (1)
ASK120067 (1)
HLX07 (1)
Hemay022 (1)
KD019 (1)
ABT-101 (0)
AC480 (0)
AG1478 (0)
BBT-207 (0)
BC3448 (0)
BMS690514 (0)
CM93 (0)
CUDC-101 (0)
EGF-PTI (0)
DF9001 (0)
DK210 (0)
STI-001 (cetuximab biosimilar) (0)
FHND9041 (0)
HLX35 (0)
HS-10375 (0)
antroquinonol (0)
zalutumumab (0)
IAE0972 (0)
IBI-334 (0)
JANX008 (0)
JNJ-26483327 (0)
JS111 (0)
MM-151 (0)
MP412 (0)
MTX-211 (0)
PF-08046052 (0)
PLB1004 (0)
PM1080 (0)
QLH11811 (0)
rindopepimut (0)
SR13668 (0)
SYN004 (0)
Sym013 (0)
TAK-186 (0)
TAK-285 (0)
TAS-121 (0)
TAVO412 (0)
THE-349 (0)
TQ-B3456 (0)
TQB3804 (0)
U3-1565 (0)
Undisclosed EGFR inhibitor (0)
XZP-5809 (0)
simotinib (0)
ZN-e4 (0)
AST1306 (0)
SY101 (0)
Ami-LC (0)
TY-9591 (0)
EMB-01 (0)
cetuximab biosimilar (0)
cipatinib (0)
ABT-806 (0)
MEHD7945A (0)
RO5083945 (0)
TL007 (0)
EMD 72000 (0)
PF-06747775 (0)
JNJ-64041757 (0)
KBP-5209 (0)
SKLB-1028 (0)
AZD8931 (0)
savolitinib (29)
tepotinib (24)
capmatinib (23)
TPX-0022 (8)
CKD-702 (6)
LY2801653 (6)
TQ-B3101 (6)
gumarontinib (5)
WXSH0011 (5)
ARQ 197 (5)
REGN5093 (4)
MGCD265 (4)
AMG 102 (4)
envonalkib (3)
ABN401 (3)
BPI-9016M (2)
HQP8361 (2)
HS-10241 (2)
S95027 (2)
APL-101 (2)
AV-299 (2)
GSK1363089 (2)
DO-1 (1)
GST-HG16 (1)
JNJ-38877605 (1)
KRC-108 (1)
SGX523 (1)
SU11274 (1)
LY2875358 (1)
E7050 (1)
RG3638 (1)
AL2846 (0)
AMG 208 (0)
AMG 337 (0)
ARGX-111 (0)
ASKC202 (0)
ASLAN002 (0)
DO-2 (0)
EMD 1204831 (0)
HLX55 (0)
MRX34 (0)
PF-04217903 (0)
PHA665752 (0)
RXDX-106 (0)
S-49076 (0)
SAIT301 (0)
SAR 125844 (0)
SPH 3348 (0)
DCC-2701 (0)
BMS-794833 (0)
h224G11 (0)
XL092 (0)
cetuximab (347)
osimertinib (301)
erlotinib (235)
afatinib (227)
gefitinib (194)
panitumumab (123)
lapatinib (107)
neratinib (102)
pyrotinib (79)
brigatinib (50)
icotinib (45)
aumolertinib (39)
amivantamab-vmjw (25)
firmonertinib (14)
mobocertinib (12)
lazertinib (12)
BGB-283 (12)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
nimotuzumab (6)
BLU-945 (6)
ASLAN001 (6)
BBT-176 (5)
CL-387785 (5)
GB263T (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
tomuzotuximab (4)
JIN-A02 (4)
TAS2940 (4)
VRN11 (4)
MET306 (4)
EGF816 (4)
AFM24 (3)
BLU-701 (3)
GC-1118A (3)
necitumumab (3)
befotertinib (3)
zorifertinib (3)
BCA101 (3)
S95026 (3)
ASP8273 (3)
DZD9008 (3)
SZMD4 (3)
ACE2016 (2)
BI-732 (2)
BLU-451 (2)
Bay846 (2)
ERAS-801 (2)
OBX02-011 (2)
olmutinib (2)
QL1203 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
APL-103 (1)
BAY 2927088 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
KKI04 (1)
PH001 (1)
rilertinib (1)
TAS3351 (1)
TRX-221 (1)
WSD0922 (1)
JMT101 (1)
S-222611 (1)
HMPL-813 (1)
SI-B001 (1)
ASK120067 (1)
HLX07 (1)
Hemay022 (1)
KD019 (1)
ABT-101 (0)
AC480 (0)
AG1478 (0)
BBT-207 (0)
BC3448 (0)
BMS690514 (0)
CM93 (0)
CUDC-101 (0)
EGF-PTI (0)
DF9001 (0)
DK210 (0)
STI-001 (cetuximab biosimilar) (0)
FHND9041 (0)
HLX35 (0)
HS-10375 (0)
antroquinonol (0)
zalutumumab (0)
IAE0972 (0)
IBI-334 (0)
JANX008 (0)
JNJ-26483327 (0)
JS111 (0)
MM-151 (0)
MP412 (0)
MTX-211 (0)
PF-08046052 (0)
PLB1004 (0)
PM1080 (0)
QLH11811 (0)
rindopepimut (0)
SR13668 (0)
SYN004 (0)
Sym013 (0)
TAK-186 (0)
TAK-285 (0)
TAS-121 (0)
TAVO412 (0)
THE-349 (0)
TQ-B3456 (0)
TQB3804 (0)
U3-1565 (0)
Undisclosed EGFR inhibitor (0)
XZP-5809 (0)
simotinib (0)
ZN-e4 (0)
AST1306 (0)
SY101 (0)
Ami-LC (0)
TY-9591 (0)
EMB-01 (0)
cetuximab biosimilar (0)
cipatinib (0)
ABT-806 (0)
MEHD7945A (0)
RO5083945 (0)
TL007 (0)
EMD 72000 (0)
PF-06747775 (0)
JNJ-64041757 (0)
KBP-5209 (0)
SKLB-1028 (0)
AZD8931 (0)
savolitinib (29)
tepotinib (24)
capmatinib (23)
TPX-0022 (8)
CKD-702 (6)
LY2801653 (6)
TQ-B3101 (6)
gumarontinib (5)
WXSH0011 (5)
ARQ 197 (5)
REGN5093 (4)
MGCD265 (4)
AMG 102 (4)
envonalkib (3)
ABN401 (3)
BPI-9016M (2)
HQP8361 (2)
HS-10241 (2)
S95027 (2)
APL-101 (2)
AV-299 (2)
GSK1363089 (2)
DO-1 (1)
GST-HG16 (1)
JNJ-38877605 (1)
KRC-108 (1)
SGX523 (1)
SU11274 (1)
LY2875358 (1)
E7050 (1)
RG3638 (1)
AL2846 (0)
AMG 208 (0)
AMG 337 (0)
ARGX-111 (0)
ASKC202 (0)
ASLAN002 (0)
DO-2 (0)
EMD 1204831 (0)
HLX55 (0)
MRX34 (0)
PF-04217903 (0)
PHA665752 (0)
RXDX-106 (0)
S-49076 (0)
SAIT301 (0)
SAR 125844 (0)
SPH 3348 (0)
DCC-2701 (0)
BMS-794833 (0)
h224G11 (0)
XL092 (0)
›
Associations
(3)
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
MCLA-129
Sensitive: C2 – Inclusion Criteria
MCLA-129
Sensitive
:
C2
MCLA-129
Sensitive: C2 – Inclusion Criteria
MCLA-129
Sensitive
:
C2
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
osimertinib + MCLA-129
Sensitive: C3 – Early Trials
osimertinib + MCLA-129
Sensitive
:
C3
osimertinib + MCLA-129
Sensitive: C3 – Early Trials
osimertinib + MCLA-129
Sensitive
:
C3
EGFR E746_A750del
Non Small Cell Lung Cancer
EGFR E746_A750del
Non Small Cell Lung Cancer
MCLA-129
Sensitive: D – Preclinical
MCLA-129
Sensitive
:
D
MCLA-129
Sensitive: D – Preclinical
MCLA-129
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login